Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma

ConclusionCamrelizumab plus albumin paclitaxel and carboplatin were found to be safe and effective in the neoadjuvant treatment of borderline resectable or unresectable locally advanced esophageal cancer. It was observed to improve the rate of curative resection without increasing perioperative complications.

https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.15232?af=R

Source: Thoracic Cancer - February 6, 2024 Category: Cancer & Oncology Authors: Li Chao, Jianting Liu, Yun Chen, Yuhui Fan, Shiping Guo, Shuangping Zhang Tags: ORIGINAL ARTICLE Source Type: research